A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Phosphatidylcholine (Primary) ; Mesalazine
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PROTECT-3
  • Sponsors Prometheus Laboratories
  • Most Recent Events

    • 13 Jun 2017 Status changed from recruiting to discontinued.
    • 26 Jul 2016 Status changed from planning to recruiting.
    • 16 Sep 2015 According to a Lipid Therapeutics media release, this trial is expected to start in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top